Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER

Nature Communications

Volumn 5, Issue , 2014, Pages

  Van Den Beucken, Twan ^a,b   Koch, Elizabeth ^a,c   Chu, Kenneth ^d   Rupaimoole, Rajesha ^e   Prickaerts, Peggy ^b   Adriaens, Michiel ^f,g   Voncken, Jan Willem ^b   Harris, Adrian L ^h   Buffa, Francesca M ^h   Haider, Syed ^d   Starmans, Maud H W ^b,d   Yao, Cindy Q ^c,d   Ivan, Mircea ⁱ   Ivan, Cristina ^e   Pecot, Chad V ^e   Boutros, Paul C ^c,d,j   Sood, Anil K ^e   Koritzinsky, Marianne ^a,c   Wouters, Bradly G ^a,b,c,d  

^a University Health Network   (Canada)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF TORONTO   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h JOHN RADCLIFFE HOSPITAL   (United Kingdom)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DICER; MICRORNA; MICRORNA 200; OXYGEN; TRANSCRIPTION FACTOR ZEB1; DEAD BOX PROTEIN; DICER1 PROTEIN, HUMAN; RIBONUCLEASE III;

CANCER; ENZYME ACTIVITY; GENE EXPRESSION; HYPOXIA; PHENOTYPE; PUBLIC HEALTH; RNA; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CELL HYPOXIA; CONTROLLED STUDY; DICER GENE; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; RNA PROCESSING; STEM CELL; TRANSCRIPTION REGULATION; BREAST TUMOR; CANCER STEM CELL; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; CELL HYPOXIA; DEAD-BOX RNA HELICASES; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NEOPLASTIC STEM CELLS; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RIBONUCLEASE III; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 84923289688     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6203     Document Type: Article

References (71)

1. Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-292 (2011).
2. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
3. Filipowicz, W., Bhattacharyya, S. N. & Sonenberg, N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102-114 (2008).
4. Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R. & Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 39, 673-677 (2007).
5. Kumar, M. S. et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 23, 2700-2704 (2009).
6. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
7. Martello, G. et al. A microRNA targeting dicer for metastasis control. Cell 141, 1195-1207 (2010).
8. Melo, S. A. et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 18, 303-315 (2010).
9. Melo, S. A. et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat. Genet. 41, 365-370 (2009).
10. Su, X. et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467, 986-990 (2010).
11. Ebert, M. S. & Sharp, P. A. Roles for microRNAs in conferring robustness to biological processes. Cell 149, 515-524 (2012).
12. Grelier, G. et al. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br. J. Cancer 101, 673-683 (2009).
13. Karube, Y. et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 96, 111-115 (2005).
14. Merritt, W. M. et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. New Engl. J. Med. 359, 2641-2650 (2008).
15. Levy, C. et al. Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell 141, 994-1005 (2010).
16. Ho, J. J. et al. Functional importance of Dicer protein in the adaptive cellular response to hypoxia. J. Biol. Chem. 287, 29003-29020 (2012).
17. Vaupel, P. Prognostic potential of the pre-therapeutic tumor oxygenation status. Adv. Exp. Med. Biol. 645, 241-246 (2009).
18. Fyles, A. et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol. 20, 680-687 (2002).
19. Schindl, M. et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 8, 1831-1837 (2002).
20. Hussain, S. A. et al. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br. J. Cancer 96, 104-109 (2007).
21. Yan, M., Rayoo, M., Takano, E. A. & Fox, S. B. BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. Br. J. Cancer 101, 1168-1174 (2009).
22. Hiraga, T., Kizaka-Kondoh, S., Hirota, K., Hiraoka, M. & Yoneda, T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 67, 4157-4163 (2007).
23. Brennan, D. J. et al. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin. Cancer Res. 12, 6421-6431 (2006).
24. Vaupel, P., Briest, S. & Hockel, M. Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien. Med. Wochenschr. 152, 334-342 (2002).
25. Cairns, R. A. & Hill, R. P. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res. 64, 2054-2061 (2004).
26. Cairns, R. A., Kalliomaki, T. & Hill, R. P. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res. 61, 8903-8908 (2001).
27. Tamara Marie-Egyptienne, D., Lohse, I. & Hill, R. P. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 341, 63-72 (2012).
28. Hill, R. P., Marie-Egyptienne, D. T. & Hedley, D. W. Cancer stem cells, hypoxia and metastasis. Semin. Radiat. Oncol. 19, 106-111 (2009).
29. Das, B. et al. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 26, 1818-1830 (2008).
30. Li, Z. et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15, 501-513 (2009).
31. Keith, B. & Simon, M. C. Hypoxia-inducible factors, stem cells, and cancer. Cell 129, 465-472 (2007).
32. Chaturvedi, P. et al. Hypoxia-inducible factor-dependent breast cancermesenchymal stem cell bidirectional signaling promotes metastasis. J. Clin. Invest. 123, 189-205 (2013).
33. Lock, F. E. et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 32, 5210-5219 (2012).
34. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
35. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
36. Winter, S. C. et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 67, 3441-3449 (2007).
37. Pollard, P. J. et al. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem. J. 416, 387-394 (2008).
38. Bernstein, B. E., Meissner, A. & Lander, E. S. The mammalian epigenome. Cell 128, 669-681 (2007).
39. Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593-601 (2008).
40. Okajima, M. et al. Anoxia/reoxygenation induces epithelial-mesenchymal transition in human colon cancer cell lines. Oncol. Rep. 29, 2311-2317 (2013).
41. Chan, Y. C., Khanna, S., Roy, S. & Sen, C. K. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J. Biol. Chem. 286, 2047-2056 (2011).
42. Yang, M. H. et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 10, 295-305 (2008).
43. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
44. Shimono, Y. et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138, 592-603 (2009).
45. Blick, T. et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J. Mammary Gland Biol. Neoplasia 15, 235-252 (2010).
46. Rupaimoole, R. et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat. Commun. 5:5202 doi:10.1038/ncomms6202 (2014).
47. Shen, J. et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497, 383-387 (2013).
48. Bernstein, B. E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315-326 (2006).
49. Yap, D. B. et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451-2459 (2011).
50. Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010).
51. Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695-1699 (2008).
52. Bracken, A. P. et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323-5335 (2003).
53. Banerjee, R. et al. The tumor suppressor gene rap1GAP is silenced by miR-101- mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene 30, 4339-4349 (2011).
54. Crea, F., Paolicchi, E., Marquez, V. E. & Danesi, R. Polycomb genes and cancer: time for clinical application? Crit. Rev. Oncol. Hematol. 83, 184-193 (2012).
55. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
56. van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521-523 (2009).
57. Agger, K. et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stressinduced senescence. Genes Dev. 23, 1171-1176 (2009).
58. Barradas, M. et al. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 23, 1177-1182 (2009).
59. Tiwari, N. et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 23, 768-783 (2013).
60. Ocana, O. H. et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709-724 (2012).
61. Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S. & Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725-736 (2012).
62. Mehta, S. et al. Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. J. Natl Cancer Inst. Monogr. 2011, 71-74 (2011).
63. Konze, K. D. et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS. Chem. Biol. 8, 1324-1334 (2013).
64. Amatangelo, M. D. et al. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 12, 2113-2119 (2013).
65. Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G. & Sood, A. K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 11, 59-67 (2011).
66. Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
67. Dai, M. et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33, e175 (2005).
68. Starmans, M. H. et al. The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. Radiother. Oncol. 102, 436-443.
69. Elenbaas, B. et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15, 50-65 (2001).
70. van den Beucken, T. et al. Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response. J. Biol. Chem. 284, 24204-24212 (2009).
71. Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253-1270 (2003).